Hypothalamic-pituitary-adrenocortical activity and response to cognitive behavior therapy in unmedicated, hospitalized depressed patients

American Journal of Psychiatry

Volumn 153, Issue SUPPL., 1996, Pages 886-891

  Thase, Michael E ^a,b   Dubé, Sanjay ^a   Bowler, Kathleen ^a   Howland, Robert H ^a   Myers, Joyce E ^a   Friedman, Edward ^a   Jarrett, David B ^a  

^a W Psychiatric Institute and Clinic   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BEHAVIOR THERAPY; CLINICAL ARTICLE; COGNITION; DEPRESSION; DEXAMETHASONE SUPPRESSION TEST; HUMAN; HYDROCORTISONE URINE LEVEL; HYPERCORTISOLISM; HYPOPHYSIS ADRENAL SYSTEM; MEDICAL RESEARCH; NEUROBIOLOGY; PRIORITY JOURNAL; PSYCHOTHERAPY; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0030001038     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.153.7.886     Document Type: Article

References (42)

1. Stokes PE, Sikes CR: The hypothalamic-pituitary-adrenocortical axis in major depression. Endocrinol Metab Clin North Am 1988; 17:1-19
2. Haskett RF: The HPA axis and depressive disorders, in Biology of Depressive Disorders, Part A: A Systems Perspective. Edited by Mann JJ, Kupfer DJ. New York, Plenum, 1993, pp 171-188
3. Maes M, Maes L, Suy E: Symptom profiles of biological markers in depression: a multivariate study. Psychoneuroendocrinology 1990; 15:29-37
4. Evans DL, Nemeroff CB: The clinical use of the dexamethasone suppression test in DSM-III affective disorders: correlation with the severe depressive subtypes of melancholia and psychosis. J Psychiatr Res 1987; 21:185-194
5. Rush AJ, Weissenburger JE: Melancholic symptom features and DSM-IV. Am J Psychiatry 1994; 151:489-498
6. APA Task Force on Laboratory Tests in Psychiatry: The dexamethasone suppression test: an overview of its current status in psychiatry. Am J Psychiatry 1987; 144:1253-1262
7. Carroll BJ: The dexamethasone suppression test for melancholia. Br J Psychiatry 1982; 140:292-304
8. Free ML, Oei TPS: Biological and psychological processes in the treatment and maintenance of depression. Clin Psychol Rev 1989; 9:653-688
9. Gitlin MJ, Gerner RH: The dexamethasone suppression rest and response to somatic treatment: a review. J Clin Psychiatry 1986; 47:16-21
10. Ribeiro SCM, Tandon R, Grunhaus L, Greden JF: The DST as a predictor of outcome in depression: a meta-analysis. Am J Psychiatry 1993; 150:1618-1629
11. Kamil R, Joffe RT: Neuroendocrine testing in electroconvulsive therapy. Psychiatr Clin North Am 1991; 14:961-970
12. Rush AJ: Biological markers and treatment response in affective disorders. McLean Hosp Bull 1983; 8:38-61
13. Robbins DR, Alessi NE, Colfer MV: Treatment of adolescents with major depression: implications of the DST and the melancholic clinical subtype. J Affect Disord 1989; 17:99-104
14. Corbishley M, Beutler L, Quan S, Bamford C, Meredith K, Scogin F: Rapid eye movement density and latency and dexamethasone suppression as predictors of treatment response in depressed older adults. Curr Ther Res 1990; 47:846-859
15. McKnight DL, Nelson-Gray RO, Barnhill J: Dexamethasone suppression test and response to cognitive therapy and antidepressant medication. Behavior Therapy 1992; 1:99-111
16. Hollon SD, DeRubeis RJ, Evans MD: Combined cognitive therapy and pharmacotherapy in the treatment of depression, in Combined Pharmacotherapy and Psychotherapy for Depression. Edited by Manning DW, Frances AJ. Washington, DC, American Psychiatric Press, 1990, pp 37-64
17. Thase ME, Bowler K, Harden T: Cognitive behavior therapy of endogenous depression, part 2: preliminary findings in 16 unmedicated inpatients. Behavior Therapy 1991; 22:469-477
18. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
19. Spitzer RL, Endicott J, Robins E: Research Diagnostic Criteria: rationale and reliability. Arch Gen Psychiatry 1978; 35:773-782
20. Endicort J, Spitzer RL: A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry 1978;35:837-844
21. Linnoila M, Karoum F, Potter WZ: High correlation of norepinephrine and its major metabolite excretion rates. Arch Gen Psychiatry 1982; 39:521-523
22. Thase ME, Himmelhoch JM, Mallinger AG, Jarrett DB, Kupfer DJ: Sleep EEG and DST findings in anergic bipolar depression. Am J Psychiatry 1989; 146:329-333
23. Thase ME, Wright JH: Cognitive behavior therapy manual for depressed inpatients: a treatment protocol outline. Behavior Therapy 1991; 22:579-595
24. Shaw BF: Specification of the training and evaluation of cognitive therapists for outcome studies, in Psychotherapy Research: Where Are We and Where Should We Go? Edited by Williams JBW, Spitzer RL. New York, Guilford Press, 1984, pp 173-189
25. Endicott J, Spitzer RL, Fleiss JL, Cohen J: The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33:766-771
26. Nathan RS, Perel JM, Pollock BG, Kupfer DJ: The role of neuropharmacological selectivity in antidepressant action: fluvoxamine versus desipramine. J Clin Psychiatry 1990; 51:367-372
27. Kupfer DJ, Perel JM, Pollock BG, Nathan RS, Grochocinski VJ, Wilson MJ, McEachran AB: Fluvoxamine versus desipramine: comparative polysomnographic effects. Biol Psychiatry 1991; 29:23-40
28. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961; 4:561-571
29. Kraemer HC, Thiemann S (eds): How Many Subjects? Statistical Power Analysis in Research. Newbury Park, Calif, Sage Publications, 1987
30. Joyce PR, Paykel ES: Predictors of drug response in depression. Arch Gen Psychiatry 1989; 46:89-99
31. Rubinow DR, Post RM, Savard R, Gold PW: Cortisol hypersecretion and cognitive impairment in depression. Arch Gen Psychiatry 1984; 41:279-283
32. Reus VI: Hormonal mediation of the memory disorder in depression. Drug Development Res 1985; 4:489-500
33. McEwen BS, Gould EA, Sakai RR: The vulnerability of the hippocampus to protective and destructive effects of glucocorticoids in relation to stress. Br J Psychiatry 1992; 160:18-24
34. Axelson DA, Doraiswamy PM, McDonald WM, Boyko OB, Tupler LA, Patterson LJ, Nemeroff CB, Ellinwood EH, Krishnan KRR: Hypercortisolemia and hippocampal changes in depression. Psychiatry Res 1993; 47:163-173
35. Thase ME, Simons AD, Reynolds CF III: Abnormal electroencephalographic sleep profiles in major depression: association with response to cognitive behavior therapy. Arch Gen Psychiatry 1996; 53:99-108
36. Thase ME, Howland RH: Biological processes in depression: an updated review and integration, in Handbook of Depression. Edited by Beckham EE, Leber WR. New York, Guilford Press, 1995, pp 213-279
37. Fennell MJV, Teasdale JD, Jones S, Damlé A: Distraction in neurotic and endogenous depression: an investigation of negative thinking in major depressive disorder. Psychol Med 1987; 17: 441-452
38. Spiker DG, Kupfer DJ: Placebo response rates in psychotic and nonpsychotic depression. J Affect Disord 1988; 14:21-23
39. Haskett RF, Zis AP, Albala AA, Lohr NE, Carroll BJ: Comparison of early and delayed inpatient dexamethasone suppression tests. Psychiatry Res 1989; 27:161-171
40. Maes M, Jacobs M-P, Suy E, Minner B, Raus J: Prediction of the DST results in depressives by means of urinary-free cortisol excretion, dexamethasone levels, and age. Biol Psychiatry 1990; 28:349-357
41. De Bellis MD, Gold PW, Geracioti TD Jr, Listwak SJ, Kling MA: Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry 1993; 150:656-657
42. Barden N, Ruel JMHM, Holfboer F: Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends Neurosci 1995; 18:6-11